

COVID-19 Vaccine Bulletin 30

Vaccine Safety & Resource Updates

Quick Updates

- Check out [Wellington-Dufferin-Guelph's vaccination dashboard](#). The **total number of doses** administered in Wellington-Dufferin-Guelph (WDG) is **317,681**.
- Anyone who requires a **FIRST DOSE can DROP-IN at any of WDGPB clinic sites** during clinic hours. In the rare event that vaccine is not available they will be booked for the next available day. See [clinic locations/times on website](#).
- **All individuals** who received their first dose of COVID-19 vaccine are eligible to book/re-book their second dose appointment (at least 28 days from first dose). WDGPB has sent email/text notifications with booking information to eligible individuals. Anyone who did not receive booking information can call the Booking Helpline (see below) to book an appointment.
- When there are last-minute **extra second dose appointments** at a WDGPB clinic, a notice will be posted on social media at which point residents can drop-in for a second dose appointment. People can follow these updates on: [Facebook](#), [Twitter](#) or [Instagram](#).
- There is a **Vaccine Registration and Booking Helpline: 1-844-780-0202 (Mon-Fri, 8 am to 8 pm)** for anyone who has issues registering or booking online.
- Individuals can also receive first or second doses at a pharmacy or primary care office. To find out which pharmacies are offering Pfizer, Moderna or AstraZeneca (AZ) (second dose only) vaccine, visit covid-19.ontario.ca/vaccine-locations.
- WDG residents who received a COVID-19 vaccination **outside of Ontario** should review the information on [WDGPB website](#) and submit the [online form](#).

Vaccine Status for Wellington-Dufferin-Guelph

78% of residents 12+ received one dose!	42% of residents 12+ received two doses
Maximum number of doses administered in one week = 37,607	Total number of doses given in primary care office or pharmacy = 67,545

Age Group	First Dose	Second Dose
60+	93%	76%
50-59	82%	45%
40-49	77%	38%
30-39	72%	29%
20-29	64%	22%
12-19	63%	9%

Vaccine Safety Updates

Myocarditis/Pericarditis & mRNA Vaccines

- Review [Vaccine Bulletin #27](#) for more information on myocarditis/pericarditis.
- In Canada, up to and including June 25, 2021 there were 90 cases of myocarditis/pericarditis following mRNA vaccination reported to the Public Health Agency of Canada or Health Canada.
- Based on U.S. data from the Centers for Disease Control, the risk of myocarditis/pericarditis following mRNA in individuals 12-39 years is 4.4 per million doses after first dose and 12.6 per million doses after second dose. Also, it is notably higher among young males with a rate of 32 per million after second dose.
- Myocarditis/pericarditis is not an uncommon condition among adolescents/young adults and is associated with many other viruses and illnesses making it difficult to determine if the relationship to mRNA vaccines is causal.
- In general, cases of myocarditis/pericarditis after vaccination were mild, and symptoms improved quickly.
- Based on the information to date, Health Canada, PHAC and the CDC have stated that the benefits of the mRNA vaccines in reducing deaths and hospitalization continue to outweigh their risks.
- [National Advisory Committee on Immunizations \(NACI\) has updated their recommendations](#) in light of the current information on myocarditis/pericarditis:
 - NACI continues to strongly recommend that a complete series with an mRNA vaccine be offered to all eligible individuals without contraindications, including those 12 years of age and older.
 - Informed consent for people receiving an mRNA vaccine should include a discussion about the very rare risk of myocarditis and/or pericarditis following immunization.
 - As a precaution, NACI recommends that individuals who experienced myocarditis and/or pericarditis after a first dose of mRNA vaccine should wait to get their second dose until more information is available.

Government of Canada (June 3, 2021). [Reports of Myocarditis and Pericarditis after COVID-19 Vaccination: Communique to health practitioners.](#)

Government of Canada (July 2, 2021). [Reported Side Effects Following COVID-19 Vaccination in Canada.](#)

Centers for Disease Control (June 23, 2021). [Advisory Committee on Immunization Practices Presentation Slides for June 23, 2021.](#)

National Advisory Committee on Immunization (July 2, 2021). [Recommendations on the Use of COVID-19 Vaccines.](#)

Capillary Leak Syndrome (CLS) & AstraZeneca/COVISHIELD Vaccine

- Very rare cases of CLS have been reported following vaccination with AstraZeneca vaccine.
- CLS is a serious, potentially fatal condition causing fluid leakage from small blood vessels resulting in rapid swelling of the arms and legs, sudden weight gain, and feeling faint (due to low blood pressure) leading to organ damage. Patients with an acute episode of CLS following vaccination require urgent medical attention and treatment.
- [AZ](#) and [COVISHIELD](#) are now contraindicated in individuals who have previously experienced episodes of CLS.
- Health Canada states that the benefits of AZ/COVISHIELD in protecting Canadians from COVID-19 continue to outweigh the risk.

Health Canada Safety Alert (June 29, 2021). [AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome.](#)

Vaccine Hesitancy

- When discussing COVID-19 vaccines with your patients/, use the **PrOTCT Framework**:
 - **Pr: Presume** they will get the vaccine with positive statements.
 - **O: Offer** to share your knowledge about the facts and your experience with having had the vaccine.
 - **T: Tailor** the recommendations to their specific health concerns.
 - **C: Address** specific concerns (should not be the bulk of the conversation).
 - **T: Talk** through a specific plan for where and when to get the vaccine.

Reference

Centre for Effective Practice (April 2021). [PrOTCT Framework for COVID-19 Vaccine Discussion.](#)

Updates to Vaccine Product Monographs

- [Pfizer-BioNTech COVID-19 Vaccine Product Monograph](#) (updated June 30)
- [Moderna COVID-19 Vaccine Product Monograph](#) (updated June 30)
- [AstraZeneca COVID-19 Vaccine Product Monograph](#) (updated June 29)
- [COVISHIELD COVID-19 Vaccine Product Monograph](#) (updated June 29)

Reliable Sources of Information on Vaccines

[WDGPH Vaccine Administration Training](#)

[Public Health Agency of Canada](#)

[Government of Ontario](#)

[Ministry of Health](#)

[Public Health Ontario](#)

[Centre for Effective Practice \(CEP\)](#)

[World Health Organization](#)

[COVID-19 Studies from the World Health Organization Database](#)

[Centres for Disease Control and Prevention \(CDC\)](#)